Search Results - "Cohen, W. E."

American Cancer Society Head and Neck Cancer Survivorship Care Guideline by Cohen, Ezra E. W., LaMonte, Samuel J., Erb, Nicole L., Beckman, Kerry L., Sadeghi, Nader, Hutcheson, Katherine A., Stubblefield, Michael D., Abbott, Dennis M., Fisher, Penelope S., Stein, Kevin D., Lyman, Gary H., Pratt‐Chapman, Mandi L.

“…Answer questions and earn CME/CNE The American Cancer Society Head and Neck Cancer Survivorship Care Guideline was developed to assist primary care clinicians…”
Get full text

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) by Cohen, Ezra E W, Bell, R Bryan, Bifulco, Carlo B, Burtness, Barbara, Gillison, Maura L, Harrington, Kevin J, Le, Quynh-Thu, Lee, Nancy Y, Leidner, Rom, Lewis, Rebecca L, Licitra, Lisa, Mehanna, Hisham, Mell, Loren K, Raben, Adam, Sikora, Andrew G, Uppaluri, Ravindra, Whitworth, Fernanda, Zandberg, Dan P, Ferris, Robert L

“…Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000…”
Get full text

Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC by Saddawi-Konefka, Robert, O’Farrell, Aoife, Faraji, Farhoud, Clubb, Lauren, Allevato, Michael M., Jensen, Shawn M., Yung, Bryan S., Wang, Zhiyong, Wu, Victoria H., Anang, Nana-Ama, Msari, Riyam Al, Schokrpur, Shiruyeh, Pietryga, Ida Franiak, Molinolo, Alfredo A., Mesirov, Jill P., Simon, Aaron B., Fox, Bernard A., Bui, Jack D., Sharabi, Andrew, Cohen, Ezra E. W., Califano, Joseph A., Gutkind, J. Silvio

“…Despite the promise of immune checkpoint inhibition (ICI), therapeutic responses remain limited. This raises the possibility that standard of care treatments…”
Get full text

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer by Wang, Zhiyong, Goto, Yusuke, Allevato, Michael M., Wu, Victoria H., Saddawi-Konefka, Robert, Gilardi, Mara, Alvarado, Diego, Yung, Bryan S., O’Farrell, Aoife, Molinolo, Alfredo A., Duvvuri, Umamaheswar, Grandis, Jennifer R., Califano, Joseph A., Cohen, Ezra E. W., Gutkind, J. Silvio

“…Immune checkpoint blockade (ICB) therapy has revolutionized head and neck squamous cell carcinoma (HNSCC) treatment, but <20% of patients achieve durable…”
Get full text

Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy by Hingorani, Dina V., Allevato, Michael M., Camargo, Maria F., Lesperance, Jacqueline, Quraishi, Maryam A., Aguilera, Joseph, Franiak-Pietryga, Ida, Scanderbeg, Daniel J., Wang, Zhiyong, Molinolo, Alfredo A., Alvarado, Diego, Sharabi, Andrew B., Bui, Jack D., Cohen, Ezra E. W., Adams, Stephen R., Gutkind, J. Silvio, Advani, Sunil J.

“…Locally advanced cancers remain therapeutically challenging to eradicate. The most successful treatments continue to combine decades old non-targeted…”
Get full text

Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck by COHEN, Ezra E. W, ROSEN, Fred, STADLER, Walter M, RECANT, Wendy, STENSON, Kerstin, DEZHENG HUO, VOKES, Everett E

“…The epidermal growth factor receptor (EGFR) is a mediator of squamous cell carcinoma of the head and neck (SCCHN) development. ZD1839 is an orally active,…”
Get full text

Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report by Jeong, Ah-Reum, Forbes, Kimberly, Orosco, Ryan K, Cohen, Ezra E W

“…Germline CDKN2A mutations are a well-known cause of familial atypical multiple mole melanoma (OMIM #155601) and melanoma-pancreatic cancer syndrome (OMIM…”
Get full text

A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis by Chen, Peili, Mancini, Maria, Sonis, Stephen T, Fernandez-Martinez, Juan, Liu, Jing, Cohen, Ezra E W, Toback, F Gary

“…We have characterized a novel 21 amino acid-peptide derived from Antrum Mucosal Protein (AMP)-18 that mediates growth promotion of cultured normal epithelial…”
Get full text

Positive Surgical Margins in the 10 Most Common Solid Cancers by Orosco, Ryan K., Tapia, Viridiana J., Califano, Joseph A., Clary, Bryan, Cohen, Ezra E. W., Kane, Christopher, Lippman, Scott M., Messer, Karen, Molinolo, Alfredo, Murphy, James D., Pang, John, Sacco, Assuntina, Tringale, Kathryn R., Wallace, Anne, Nguyen, Quyen T.

“…A positive surgical margin (PSM) following cancer resection oftentimes necessitates adjuvant treatments and carries significant financial and prognostic…”
Get full text

A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors by Cohen, Ezra E. W., Pishvaian, Michael J., Shepard, Dale R., Wang, Ding, Weiss, Jared, Johnson, Melissa L., Chung, Christine H., Chen, Ying, Huang, Bo, Davis, Craig B., Toffalorio, Francesca, Thall, Aron, Powell, Steven F.

“…BackgroundExpressed on activated T and natural killer cells, 4-1BB/CD137 is a costimulatory receptor that signals a series of events resulting in cytokine…”
Get full text

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses by Cohen, E. E. W., Tortorici, M., Kim, S., Ingrosso, A., Pithavala, Y. K., Bycott, P.

“…Purpose Axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, has shown activity in advanced thyroid…”
Get full text

p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors by Kuo, Wen-Liang, Sharifi, Marina N, Lingen, Mark W, Ahmed, Omar, Liu, Jing, Nagilla, Madhavi, Macleod, Kay F, Cohen, Ezra E W

“…The phosphoinositol-3 kinase (PI3K) pathway is highly dysregulated in squamous cell carcinoma of the head and neck (SCCHN). While inhibitors of the PI3K/AKT…”
Get full text

Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4 by Wang, Zhiyong, Wu, Victoria H., Allevato, Michael M., Gilardi, Mara, He, Yudou, Luis Callejas-Valera, Juan, Vitale-Cross, Lynn, Martin, Daniel, Amornphimoltham, Panomwat, Mcdermott, James, Yung, Bryan S., Goto, Yusuke, Molinolo, Alfredo A., Sharabi, Andrew B., Cohen, Ezra E. W., Chen, Qianming, Lyons, J. Guy, Alexandrov, Ludmil B., Gutkind, J. Silvio

“…Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Tobacco use is the main risk factor for HNSCC, and tobacco-associated…”
Get full text

Single sample expression-anchored mechanisms predict survival in head and neck cancer by Yang, Xinan, Regan, Kelly, Huang, Yong, Zhang, Qingbei, Li, Jianrong, Seiwert, Tanguy Y, Cohen, Ezra E W, Xing, H Rosie, Lussier, Yves A

“…Gene expression signatures that are predictive of therapeutic response or prognosis are increasingly useful in clinical care; however, mechanistic (and…”
Get full text

Current perspectives on recurrent HPV-mediated oropharyngeal cancer by Guo, Theresa, Kang, Stephen Y, Cohen, Ezra E W

“…In the recent years, the prevalence of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) has increased significantly. Currently, nearly 80-90% of all…”
Get full text

Pharmacokinetics of single-agent axitinib across multiple solid tumor types by Tortorici, Michael A., Cohen, Ezra E. W., Pithavala, Yazdi K., Garrett, May, Ruiz-Garcia, Ana, Kim, Sinil, Fruehauf, John P.

“…Purpose Axitinib, a potent and selective inhibitor of vascular endothelial growth factor receptors, showed antitumor activity as a single agent against several…”
Get full text

SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck by Pai, Sara I, Cohen, Ezra E W, Lin, Derrick, Fountzilas, George, Kim, Edward S, Mehlhorn, Holger, Baste, Neus, Clayburgh, Daniel, Lipworth, Loren, Resteghini, Carlo, Shara, Nawar, Fujii, Takashi, Zhang, Jun, Stokes, Michael, Wang, Huifen, Twumasi-Ankrah, Philip, Wildsmith, Sophie, Khaliq, Asud, Melillo, Giovanni, Shire, Norah

“…Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell…”
Get full text

Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer by Xu, Beibei, Boero, Isabel J., Hwang, Lindsay, Le, Quynh‐Thu, Moiseenko, Vitali, Sanghvi, Parag R., Cohen, Ezra E. W., Mell, Loren K., Murphy, James D.

“…BACKGROUND Aspiration pneumonia represents an under‐reported complication of chemoradiotherapy in patient with head and neck cancer. The objective of the…”
Get full text

Modifiable risk behaviors in patients with head and neck cancer by Sivasithamparam, Janani, Visk, Carly A., Cohen, Ezra E. W., King, Andrea C.

“…BACKGROUND Use of tobacco products, excessive alcohol consumption, and high‐risk sexual behaviors increase the risk of developing head and neck cancer and…”
Get full text

Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression by Dolina, Joseph S., Lee, Joey, Brightman, Spencer E., McArdle, Sara, Hall, Samantha M., Thota, Rukman R., Zavala, Karla S., Lanka, Manasa, Ramamoorthy Premlal, Ashmitaa Logandha, Greenbaum, Jason A., Cohen, Ezra E. W., Peters, Bjoern, Schoenberger, Stephen P.

“…Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden…”
Get full text